Cargando…

Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib

Inhibition of KIT-signaling is a major molecular target for gastrointestinal stromal tumor (GIST) therapy, and imatinib mesylate (IM) is known as the most effective first-line treatment option for patients with advanced, unresectable, and/or metastatic GISTs. We show here for the first time that the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boichuk, Sergei, Galembikova, Aigul, Mikheeva, Ekaterina, Bikinieva, Firuza, Aukhadieva, Aida, Dunaev, Pavel, Khalikov, Dinar, Petrov, Semen, Kurtasanov, Refat, Valeeva, Elena, Kireev, Igor, Dugina, Vera, Lushnikova, Anna, Novikova, Maria, Kopnin, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352302/ https://www.ncbi.nlm.nih.gov/pubmed/32599808 http://dx.doi.org/10.3390/cancers12061674

Ejemplares similares

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
por: Boichuk, Sergei, et al.
Publicado: (2018)

Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair
por: Boichuk, Sergei, et al.
Publicado: (2020)

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors
por: Sergei, Boichuk, et al.
Publicado: (2020)

The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site
por: Boichuk, Sergei, et al.
Publicado: (2021)

Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline
por: Boichuk, Sergei, et al.
Publicado: (2023)

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines
por: Boichuk, Sergei, et al.
Publicado: (2021)

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
por: Boichuk, Sergei, et al.
Publicado: (2017)

Computational-Based Discovery of the Anti-Cancer Activities of Pyrrole-Based Compounds Targeting the Colchicine-Binding Site of Tubulin
por: Boichuk, Sergei, et al.
Publicado: (2022)

Impaired Expression of Cytoplasmic Actins Leads to Chromosomal Instability of MDA-MB-231 Basal-Like Mammary Gland Cancer Cell Line
por: Dugina, Vera, et al.
Publicado: (2021)

Interaction of microtubules with the actin cytoskeleton via cross-talk of EB1-containing +TIPs and γ-actin in epithelial cells
por: Dugina, Vera, et al.
Publicado: (2016)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Divergent impact of actin isoforms on cell cycle regulation
por: Dugina, Vera, et al.
Publicado: (2018)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Tumor promotion by γ and suppression by β non-muscle actin isoforms
por: Dugina, Vera, et al.
Publicado: (2015)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

Imatinib plasma levels: correlation with clinical benefit in GIST patients
por: Widmer, N, et al.
Publicado: (2010)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2012)

Subcapsular Liver Hematoma in Metastatic GIST Complicating Imatinib (Gleevec) Therapy
por: Shankar, Sridhar
Publicado: (2015)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
por: Zhuang, Wei, et al.
Publicado: (2018)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Cytoplasmic Beta and Gamma Actin Isoforms Reorganization and Regulation in Tumor Cells in Culture and Tissue
por: Dugina, V. B., et al.
Publicado: (2022)

Imatinib administration in two patients with liver metastases from GIST and severe jaundice
por: De Pas, T, et al.
Publicado: (2003)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
por: Vetto, John T
Publicado: (2009)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2013)

Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2014)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
por: Ghias, Adnan Asif Parvez, et al.
Publicado: (2018)

Long-Surviving Patients with Recurrent GIST after Receiving Cytoreductive Surgery with Imatinib Therapy
por: Choi, Won Hyuk, et al.
Publicado: (2009)

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
por: Seidel, Christoph, et al.
Publicado: (2012)

CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib
por: Tian, Guang-Ang, et al.
Publicado: (2016)

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
por: Bins, Sander, et al.
Publicado: (2016)

Large duodenal GIST with massive liver secondaries melting under Imatinib: a case report
por: Sankar, S, et al.
Publicado: (2008)

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
por: Deshaies, Isabelle, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_6sr778fa8g4g74l96fasfn4b66